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Abstract
Background: To evaluate the association between polymorphisms involved in DNA repair and oxidative stress
genes and mean dose to whole breast on acute skin reactions (erythema) in breast cancer (BC) patients following
single shot partial breast irradiation (SSPBI) after breast conservative surgery.
Materials and Methods: Acute toxicity was assessed using vers.3 criteria. single nucleotides polymorphisms(SNPs)
in genes: XRCC1(Arg399Gln/Arg194Trp), XRCC3 (A4541G-5’UTR/Thr241Met), GSTP1(Ile105Val), GSTA1 and RAD51
(untranslated region). SNPs were determined in 57 BC patients by the Pyrosequencing analysis. Univariate(ORs and
95% CI) and logistic multivariate analyses (MVA) were performed to correlate polymorphic genes with the risk of
developing acute skin reactions to radiotherapy.
Results: After SSPBI on the tumour bed following conservative surgery, grade 1 or 2 acute erythema was observed
in 19 pts(33%). Univariate analysis indicated a higher significant risk of developing erythema in patients with
polymorphic variant wt XRCC1Arg194Trp, mut/het XRCC3Thr241Met, wt/het XRCC3A4541G-5’UTR. Similarly a higher
erythema rate was also found in the presence of mut/het of XRCC1Arg194Trp or wt of GSTA1. Whereas, a lower
erythema rate was observed in patients with mut/het of XRCC1Arg194Trp or wt of XRCC1Arg399Gln. The mean
dose to whole breast(p = 0.002), the presence of either mut/het XRCC1Arg194Trp or wt XRCC3Thr241Met (p =
0.006) and the presence of either mut/het XRCC1Arg194Trp or wt GSTA1(p = 0.031) were confirmed as predictors of
radiotherapy-induced erythema by MVA.
Conclusions: The Whole breast mean dose together with the presence of some polymorphic genes involved in
DNA repair or oxidative stress could explain the erythema observed after SSPBI, but further studies are needed to
confirm these results in a larger cohort.
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Background
Breast cancer is the most common type of cancer
among women with an incidence rate of 13%. It is also
one of the most leading causes of death in the European
Union in breast cancer women (88,400 deaths i.e.17.4%
of total) [1-3].
Breast radiation therapy (RT) after conservative sur-
gery is now widely accepted as a standard of care for
patients with early breast cancer using a multidisciplin-
ary approach. RT destroys the breast cancer cells that
remain after surgery, reducing the risk of breast cancer
recurrence by about 70%. However RT could also gener-
ate radiation-induced side-effects in the surrounding
normal tissues [4,5]. An important to address is the
unpredictable inter-individual variability in toxicity asso-
ciated with this treatment [6,7].
Ionising radiation acts directly on cellular macromole-
cules (DNA, RNA, proteins, etc.), or indirectly through
the production of reactive oxygen species and subsequent
by-products able to modify bio-molecules. The response
of eukaryotic cells to ionising radiation includes and
influences several DNA damage repair pathways with
subsequent full ‘biological’ recovery or cell death [8,9]. In
particular, XRCC1 (x-ray repair cross-complementation
group 1) is one of the molecules involved in the restora-
tion phase of the base excision repair (BER) pathway.
XRCC3 (x-ray repair cross-complementation group 3)
allows double strand breaks to be efficiently repaired via
the homologous recombination repair pathway, for cor-
rect chromosomal segregation and of DNA cross links
repair [3,10]. Antioxidant enzymes, such as glutathione-
S-transferases (GSTs) are activated as a result of RT [11]
and are involved in detoxifying of the damage caused by
oxidative stress. RAD51 is a member of the RAD51 pro-
tein family, involved in the Homologous Recombination
(HR) and repair of DNA. This protein is thought to play
a role in homologous pairing and the strand transfer of
DNA, and is also found to interact with BRCA1 and
BRCA2 in the cellular response to DNA damage.
Various authors [3,8,12-16] have investigated the asso-
ciation between the polymorphic nature of these genes
and the possibility of developing biomarkers or predictive
assays for radio-sensitivity of tissues acutely treated with
ionizing radiation in breast cancer patients. However,
further studies are needed to reach any final conclusions.
A number of studies [14,17-21] reported that most
(81% - 100%) intra-breast tumour recurrences after
breast conserving surgery (BCS) occur in close proximity
to the tumour bed, thereby providing the rationale for
adjuvant radiotherapy limited to this area [22]. This evi-
dence has supported a new philosophy of Partial Breast
Irradiation (PBI). In fact, it has been speculated that by
confining the dose delivery to a smaller treatment
volume, a larger radiation fraction size could be used
without an unacceptable increase in acute/late toxicity.
Thus, accelerated partial breast irradiation (APBI) has
been promoted in phase I-III trials designed to test the
feasibility and equivalence with the standard Whole
breast irradiation (WBI) in properly selected low risk
early breast cancer patients after BCS.
The aim of this study is to identify marker genes able
to predict an increased risk of acute skin toxicity in
patients undergoing a single high dose of PBI after BCS
at the Regina Elena Italian National Cancer Institute.
In particular, we investigated the following specific poly-
morphic genes: XRCC1 (Arg399Gln, and Arg194Trp),
XRCC3 (A4541G-5’UTR and Thr241Met), GSTP1 (Ile105-
Val), GSTA1 and RAD51 (untranslated region) in order to
assess the relationship with an increased susceptibility of
acute adverse effects induced by radiotherapy.
Methods
Radiation treatment
From March 2006 to January 2008, patients who under-
went BCS and sentinel node biopsy and/or axillary dissec-
tion for early breast adenocarcinoma and who met the
eligibility criteria were treated in prone position. An adju-
vant single dose 3D conformal radiation therapy (3D-
CRT) APBI schedule was administered to the Index Area.
The eligibility criteria included: Age ≥ 48 years with a life
expectancy of at least 5 years, post-menopausal status, his-
tologically proven, non lobular, adenocarcinoma of the
breast, primary tumours ≤ 3 cm, negative surgical margins
(≥ 2 mm), negative sentinel nodes or < 4 positive axillary
nodes, no extra-capsular extension, no previous radiother-
apy. The exclusion criteria comprised of the following:
multicentric disease, extended intraductal component
(EIC > 25%), Paget’s disease, lobular adenocarcinoma, dis-
tant metastases. All the above criteria enable the identifi-
cation of patients at low risk of local recurrence. The
study was conducted in accordance with the Helsinki
Declaration. Each patient was informed in advance about
the study protocol in written form (informed consent) and
verbal. The patient was given ample opportunity to
request relevant information regarding the study and
decide with full autonomy whether to participate in the
protocol. The protocol was approved by the local Ethics
and Scientific Committee of the Regina Elena Italian
National Cancer Institute (reference number IFO-84/10).
From March 2006 to January 2008, 57 patients matched
the eligibility criteria and provided a written informed
consent. Instead of given an equivalent conventional treat-
ment consisting of 50 Gy (25 daily fractions of 2 Gy in 5-6
week treatments) a single dose was used. The dose of 18
Gy was used in the first 4 patients to test the feasibility of
the protocol and whether it was well tolerateda dose a of
Falvo et al. BMC Cancer 2011, 11:291
http://www.biomedcentral.com/1471-2407/11/291
Page 2 of 9
21 Gy was administered to the other patients. The dose
was delivered to a portion of breast parenchyma corre-
sponding to the tumour bed after surgery. Dose volume
constraints were used in order to reduce the dose to nor-
mal breast tissue and skin. The major technical details of
our approach were reported previously in a separate paper
[23].
Study design
The SSPBI trial was designed as a prospective Phase II sin-
gle-arm study. The use of a single dose tumour bed is
expected to be very effective in terms of tumour control,
but it could increase the incidence of radiation induced
erythema. Therefore, we assumed that a decreased DNA
repair capability, as well as a reduced detoxification of the
damage caused by oxidative stress could explain the
increased acute toxicity, i.e. a higher incidence of erythema
after a single dose. It is for this reason we decided to inves-
tigate SNPs of genes involved in antioxidant and DNA
damage repair pathways such as GST, XRCC1, XRCC3
and RAD51.
We assumed an erythema rate of 20% and 54% in
patient groups at low and high risk, respectively, (groups
were identified based on the absence/presence of the
above polymorphisms alone or in combination). Thus the
minimum sample size was 56 patients with a = 0.05, 2-
tailed test and a power of the study of 80%.
End-points
Acute toxicity (i.e. erythema), was the end-point described
in the analysis and was assessed using the Regina Elena
Italian National Cancer Institute common terminology cri-
teria for adverse events (CTCAE, version 3.0) [24], and
was defined as acute if it occurred within the first six
months after radiotherapy. Grade refers to the severity of
the Adverse Event (AE). Briefly, Grade 1 indicates faint
erythema or dry desquamation, G2 moderate to brisk
erythema, G3 moist desquamation other than skin folds
and creases and G4 skin necrosis of ulceration of full
thickness dermis.
Sample collection and laboratory analysis
All subjects enrolled in the study provided samples of
blood, approximately 5 ml, in sterile tubes containing
ethylenediaminetetracetic acid (EDTA). Whole blood sam-
ples for DNA analyses were immediately frozen at -80°C
until processing.
Molecular analysis
Genomic DNA was isolated from cells in the venous
blood using QIAmp kit (QIAmp DNA blood Mini Kit,
Qiagen, Valencia, CA), following the manufacturer’s
instructions, and the DNA quality was evaluated by the
spectrophotometer analysis (NanoDrop instrument).
Specific primers included in the Radiotherapy Response
kit (Diathec Company, Italy) were used in the DNA
amplification experiments. The desired DNA was ampli-
fied by Real-Time PCR using Rotorgene Instrument
(Corbett) following polymerase chain reaction (PCR)
conditions provided by the manufacturer. The following
polymorphisms were evaluated: XRCC3 C18067T
(Thr241Met), XRCC3 A4541G (5’-UTR untranslated
region), XRCC1 G28152A (Arg399Gln), GSTP1 A313G
(Ile105Val) RAD51 G135C (untranslated region).
Other polymorphisms such as GSTA1 and XRCC1
Arg194Trp, which were not included in the above kit,
were carried out and tested. The ad-hoc designed primers
for these genes are illustrated in Table 1 and PCR reac-
tions were carried out in a volume of 50 μl containing:
10 mM Takara deoxynucleotide triphosphate (dNTP) mix-
ture, 20 pmol primers, approximately 30 ng of DNA tem-
plate, Takara 5XR-PCR Buffer (Mg2+free), Takara 50 mM
Mg2+, EvaGreen TM Dye 20 × and Takara Ex TaqR-PCR
Custom (5U/ul). Reaction conditions were as follows:
initial denaturation at 95°C for 3 min then 35-cycles of
denaturation at 95°C for 30 sec; annealing at 56°C
(GSTA1) or at 62°C (XRCC1 Arg194Trp) for 30 sec; elon-
gation at 72°C for 30 sec and final extension at 60°C for
5 min, then 5-cycles of green channel signal acquisition at
60°C for 30 sec. PCR products were evaluated on 2.5 %
agarose gel stained with ethidium bromide. In addition,
one control for each genotype of GSTA1 and XRCC1
Arg194Trp was generated.
The target sequence containing the polymorphic site
was amplified using standard PCR conditions in which
one of the primers was biotinylated. A single-strand tem-
plate was generated by removing the non-biotinylated
strand on streptavidin coated beads (matrix). The bound
DNA template on the affinity matrix was separated by
denaturation in NaOH and used for the following synth-
esis of a short strand (10-15 bases) of DNA adjacent to the
SNP site. The specific sequence primers used for GSTA1
and XRCC1 Arg194Trp were also reported in Table 1.
The polymorphisms were analyzed using Pyrosequencing
technologies (instrument PyroMark MD-Biotage, Uppsala,
Sweden) according to a previously published method
[25,26].
Statistical analysis
In order to determine predictors of acute toxicity, retro-
spectively, we evaluated the following polymorphisms:
XRCC3 C18067T (Thr241Met), XRCC3 A4541G (5’-
UTR), XRCC1 G28152A (Arg399Gln), GSTP1 A313G
(Ile105Val) RAD51, G135C (untranslated region) GSTA1
and XRCC1 Arg194Trp. In addition, we also analyzed
combined genotypes according to the literature.
Odds ratios (ORs) and 95% confidence intervals (CIs),
Chi-squared and Fisher exact (2-sided) tests were
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calculated. A OR > 1.0 indicates an increased risk of
erythema in patients with a polymorphic gene.
Patient characteristics, polymorphisms and dosimetric
data, selected as significant by the Univariate analysis,
were included in a logistic regression analysis in the
multivariate model, which included mean dose to whole
breast (WB) and to skin, age at the time of treatment
and all polymorphisms.
Statistically significant associations between poly-
morphisms and side effects were indicated by a p-value <
0.05. The sample size was calculated with Sample Power,
the odds risks with an R-package, and the Forest plots
with Medcalc.
Results
For the purpose of this study, 57 eligible patients were
available for determining polymorphisms. Out of the 57
patients, 15 (26%) were also treated with adjuvant non-
concomitant chemotherapy, as reported in Table 1. The
adjuvant chemotherapy had been completed 3 to 4 weeks
before RT with the exception of one patient (who under-
went chemotherapy one-week after SSPBI). Adjuvant hor-
mone-therapy, with Tamoxifen (6 pts), Anastrozole
(38 pts) or Letrozole (8 pts), as indicated, were given
simultaneously with SSPBI. The median follow-up of the
patient groups which underwent SSPBI was 38 months
(range 19-50).
However, there was no evidence of chemotherapy
induced toxicity at the start of RT. Patient, tumour and
treatment related characteristics are listed in Table 2.
Polymorphisms
Pyrosequencing is a sequencing method performed by
synthesis, a simple to use technique for accurate and con-
sistent analysis of large numbers of short to medium
length DNA sequences. Each result, called a “pyrogram”,
indicates a determined polymorphic position, providing
useful information to identify a category of patients with
increased risk of toxicity.
For GSTA1 and XRCC1 Arg194Trp polymorphisms
that are not included in the Radiotherapy kit, a method
assay to validate them was developed and the typical
pyrograms obtained are depicted in Figure 1. In this fig-
ure, the peak is proportional to the amount of nucleo-
tides incorporated. The sequencing events are obtained
in real time and the resulting genotypes of GSTA1 and
XRCC1 Arg194Trp are depicted inside the yellow area.
Each gene can generate three distinct pyrosequencing
patterns, corresponding to homozygote wild type, het-
erozygote or homozygote mutant. The polymorphism
was determined and the results are shown in Table 3.
Acute toxicity
Acute erythema was observed in 19 patients (33%),
divided in Grade 1 (G1) in 11 (19%) and Grade 2 (G2)
Table 1 Polymorphic genes with reference sequence [rs], PCR and sequence primers, products size and annealing
conditions
Gene NCBI
dbSNP ID
Primers PCR
product
size (bp)
PCR
Annealing
temp.
XRCC1 Arg194Trp [rs1799782] PCR Forward:
5’-GCCGGGGGCTCTCTTCTT-3’
PCR Reverse biot:
5’-CTCACTCAGGACCCACGTTGT-3’
Pyrosequence:
5’-GGGGCTCTCTTCTTCA-3’
75bp 62°C
GSTA1 [rs3957356] PCR Forward:
5’-GGCTCGACAACTGAATTCCA-3’
PCR Reverse biot:
5’-TGGCTTTTCCCTAACTTGACTCT-3’
Pyrosequence:
5’-GACTCTTCTTTCAGTGGG-3’
101 bp 56°C
Abbreviations: NCBI = National Center for Biotechnology Information, ID = identification.
Table 2 Main patient and tumor characteristics
Age (years) median (range) 66 (51-87)
Histology Ductal/other 48/9
Estrogen receptor RE+/RE- 52/5
Progesteron receptor RP+/RP- 45/12
Tumor stage Tis/T1/T2 1/48/8
Nodal stage N0/N1 54/3
Chemotherapy yes/no 15/42
CMF 5
FEC 5
EC 1
EC+ Docetaxel 4
Hormone-therapy yes/no 52/5
Abbreviations: CMF: Cyclophosphamide (600 mg/m2, Methotrexate 40 mg/m2,
5-FU 600 mg/m2 d 1 and d 8 q 4 weeks × 6); FEC (5-FU 600 mg/m2,
Epirubicin 60 mg/m2, Cyclophosphamide 600 mg/m2 d 1 q 3 weeks × 6); EC
(Epirubicin 60 mg/m2, Cyclophosphamide 600 mg/m2 d1 q 3 weeks × 4); EC+
Docetaxel : EC followed by Docetaxel (100 mg/m2 d1 q 3 weeks × 4)
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in 8 (14%) patients. No erythema was detected in 38
patients (67%). A statistically significant correlation was
found between the ≥G1 erythema and the mean dose to
WB (p = 0.008).
The ORs of any grade of erythema (with 95% CI and
p-values) are reported in Table 4, by distinguishing the
patients on the basis of the polymorphic genes. We
found a significant incidence of erythema rate in
patients with the polymorphic variant (AA i.e. wt) of
XRCC1 Arg194Trp with greater odds (OR = 8.07; 95%
CI, 1.02-373.8). The allelic variant wt of XRCC3
Thr241Met is associated with a lower rate of erythema
(OR = 0.29; 95% CI, 0.05-1.29). A toxic role of allelic
variant (wt/het i.e AA/Aa) of XRCC3A4541G-5’UTR
was also found (OR = 0.49; 95% CI, 0.01-40.29).
Our results show a level that is not statistically signifi-
cant in the protection towards developing an erythema,
i.e. lower odds (OR = 0.3; 95% CI, 0.08-1.08), in the pre-
sence of at least one allelic variant (mut/het i.e. aa/Aa)
of XRCC1 Arg194Trp or of GSTP1 (Ile105Val). The pre-
sence of the polymorphic variant mut/het of XRCC1
Arg194Trp and wt of XRCC3 Thr241Met results signifi-
cantly in the protection towards developing an erythema
with lower odds (OR = 0.2; 95% CI: 0.04-0.78).
Furthermore, the association between the polymorphic
variant mut/het of XRCC1 Arg194Trp and the wt of
Figure 1 Typical raw data obtained using Pyrosequencing instruments for GSTA1 and XRCC1 Arg194Trp polymorphisms. Note: the
yellow area indicates the resulting genotypes of GSTA1 and XRCC1 Arg194Trp.
Table 3 Polymorphism distribution
Gene SNPs ds SNP ID Observed Genotype
(n. Pts)
allele frequencies(%) %CEU
AA Aa aa allele A allele
a
allele A allele a
XRCC3 A4541G (rs1799794) 32 23 2 78% 22% 74% 26%
XRCC3 Thr241Met (rs861539) 18 33 6 61% 39% 61% 39%
XRCC1 Arg399Gln (rs25487) 31 23 3 75% 25% 57% 43%
GSTP1 Ile105Val (rs1695) 32 22 3 75% 24% 65% 35%
RAD51 G135C (rs1801320) 54 3 / 96% 4% 97% 3%
GSTA1 G > A (rs3957356) 12 35 10 53% 47% 61% 32%
XRCC1 Arg194Trp (rs1799782) 44 12 1 88% 12% 76% 24%
Abbreviations: %CEU = frequencies in European population.
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XRCC1 Arg399Gln shows a protective role towards
erythema (OR = 0.39; 95% CI: 0.1-1.35). While, the asso-
ciation between the polymorphic variant mut/het of
XRCC1 Arg194Trp or wt of GSTA1 results in a higher
risk of erythema (OR = 6.01; 95% CI, 1.16-61.04).
Forest plots (Figure 2 panels A-E) show the acute skin
toxicity observed in our cohort and in literature, by dis-
tinguishing the patients based on the presence of alleles
of some polymorphic genes. A protective role (as trend)
of mut/het XRCC1 Arg194Trp was found, in contrast to
data by Mangoni et al. [12] that reported a slightly toxic
effect (Figure 2A). A significant function of wt XRCC1
Arg399Gln as toxic agent was observed according to data
reported by Popanda et al. [13] and Mangoni et al. [12]
(Figure 2B). Next, the trend as a toxic factor of the wt
XRCC3 Thr241Met was found, according to Chang-
Claude et al. [14]; as well as of wt GSTA1, as reported by
Ambrosone et al. [15] who described this gene as protec-
tive agent (Figure 2C-D). Further, we found a protective
role as trend for wt GSTP1 in contrast to Ambrosone
et al. [15] (Figure 2E). In fact, no statistical significance
for wt GSTP1 was found to distinguish acute toxicity in
patients in either of the studies. Finally, no correlation
was found between acute toxicity and mut/het RAD51.
Multivariate analysis confirmed the mean dose to WB
(p = 0.002), the presence of mut/het XRCC1 Arg194Trp
or wt XRCC3 Thr241Met (p = 0.006) and the presence of
mut/het XRCC1 Arg194Trp or wt GSTA1 (p = 0.031) as
predictors of erythema. In addition, when identifying the
low and high risk groups, according to the absence or
presence of mut/het XRCC1 Arg194Trp or wt XRCC3
Thr241Met, the observed erythema in our cohort was
20% and 59%, respectively. Assuming an a = 0.05 and a
2-tailed test, the power of the study was 78% with 38 and
19 patients in low and high risk groups respectively;
when assuming an a = 0.05 and a 1-tailed test was used
the power of the study was 80%.
Discussion
In this paper we evaluated the effects of polymorphisms
in encoding genes for enzymes involved in DNA repair
and in protection from ROS (reactive oxygen species), in
relation to acute skin side effects of RT. In particular, the
following polymorphic genes are involved in oxidative
stress-related mechanisms (GSTs) and in DNA repair
were taken into consideration: XRCC1(Arg399Gln/
Arg194Trp), XRCC3(A4541G-5’UTR /Thr241Met),
GSTP1(Ile105Val), GSTA1 and RAD51(untranslated
region), which are involved in oxidative stress-related
mechanisms (GSTs) and in DNA repair.
A statistically significant positive connection was
found between the ≥G1 erythema and wt XRCC1
Arg194Trp, confirming the trend reported by Chang-
Claude J et al. [14]. Likewise, an association between
XRCC1 Arg194Trp and skin reactions was also been
described by Mangoni M. et al. [12]. Also in our study,
the wt XRCC3 Thr241Met showed a trend for having a
protective role towards of erythema, according to data
Table 4 ORs of erythema for different polymorphisms and their combination
Polymorphisms Genotype Percentage
of ≥G1
OR
(95% CI)
Chi-squared p-value Fisher’s exact test p-value
XRCC1 Arg194Trp (Aa/aa) 8% 1
(AA) 41% 8.07 (1.02-373.8) 0.026 0.042
XRCC3 Thr241Met (Aa/aa) 41% 1
(AA) 17% 0.29 (0.05-1.29) 0.07 0.081
XRCC3 A4541G (5’UTR) (aa) 50% 1
(AA/Aa) 33% 0.49 (0.01-40.29) 0.611 1
XRCC1Arg194Trp/GSTP1 Others 50% 1
XRCC1(Aa/aa)
or GSTP1 (Aa/aa)
23% 0.3 (0.08-1.08) 0.034 0.046
XRCC1Arg194Trp/XRCC3 Thr241Met § Others 48% 1
XRCC1 (Aa/aa) or
XRCC3 (AA)
15% 0.2 (0.04-0.78) 0.008 0.011
XRCC1 Arg194Trp/XRCC1 Arg399Gln Others 46% 1
XRCC1 Arg194Trp
(Aa/aa) or XRCC1
Arg399Gln (AA)
24% 0.39 (0.1-1.35) 0.088 0.099
XRCC1 Arg194Trp/GSTA1 # Others 11% 1
XRCC1 (Aa/aa) or
GSTA1 (AA)
44% 6.01 (1.16-61.04) 0.016 0.018
Abbreviations: OR = odds ratio; calculated to homozygous normal genotype; 95% CI = 95% confidence interval.
§ a = 0.05, 2-tailed power (1-b = 78%; a = 0.05, 1- tailed power > 80%
# a = 0.05, 2-tailed power (1-b = 75%; a = 0.05, 1- tailed power > 80%
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Figure 2 (a) Forest plot summarizes a pooled analysis of acute erythema distinguishing patients with/without (A) wt XRCC1
Arg194Trp; (B) wt XRCC3 Thr241Met; (C) wt XRCC1 Arg399Gln; (D) GSTA1; (E) GSTP1. The mutation is toxic or protective when OR is
higher or lower than 1, respectively.
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reported by Popanda et al. [13] and Mangoni M. et al.
[12].
It is worthy to note that, Cecchin et al. [27] investigated
the role of XRCC3A4541G-5’UTR, a non-coding poly-
morphism in the 5’UTR of the gene with an un-clarified
effect on protein expression, in rectal cancer patients. The
Authors suggested a protective role of the variant allele
XRCC3A4541G-5’UTR toward radiation injury. It is
important to stress that a statistically significant positive
association correspondence was found between ≥G1
erythema and wt/het XRCC3A4541G-5’UTR also in our
study, indicating the protective role of the variant allele
towards radiation injury also regards to breast cancer.
Whereas, no statistically significant correlation was found
with other polymorphisms and erythema.
Due to the limited number of studies involving poly-
morphisms and also the limited number of toxic events
reported in literature, a pooled analysis was performed for
acute toxicity and was been shown as a Forest plot. This
analysis has confirmed the role of some polymorphic var-
iants as predictors of acute toxicity, although in many
cases only as a trend (Figure 2).
We also performed tests to assess the association of
different genes involved in developmental clinical radio-
sensitivity. Particular, we tested whether there was a
possible association between the variant mut/het of dif-
ferent genes.
The presence of the polymorphic variant mut/het of
XRCC1 Arg194Trp or wt of XRCC1 Arg399Gln showed
evidence of a protective role towards erythema. On the
contrary, in the study by Mangoni et al. [12] the pre-
sence of XRCC1 Arg194Trp variant allele and XRCC1
Arg399Gln wt allele suggested a significant risk of toxi-
city induced by radiotherapy.
In the present study, a correlation was also found
between the absence of erythema and the presence of a
mut/het of XRCC1 Arg194Trp or of the wt XRCC3
Thr241Met, indicating the protective role of these
alleles.
Further, the association of erythema with the presence
of a mut/het of XRCC1 Arg194Trp or mut/het of
GSTP1 was also found to be statistically significant indi-
cating the protective role of these polymorphisms. In
addition, a high rate of erythema was correlated with
the mut/het of XRCC1 Arg194Trp or with of the wt
GSTA1, while a trend toward having a protective factor
was observed when a mut/het of XRCC1 Arg194Trp or
the wt XRCC1 Arg399Gln alleles were expressed.
Conclusions
This study shows a statistically significant positive rela-
tionship between ≥G1 erythema and the wt/het
XRCC3A4541G-5’UTR polymorphism, indicating a pro-
tective role of the variant allele towards radiation injury
in BC patients who underwent SSPBI. The reported
multivariate analysis suggests that SNP (XRCC1 or wt
XRCC3 Thr241Met and XRCC1 or GSTA1) and dosi-
metric data (mean dose to whole breast) may be suc-
cessfully used to predict acute toxicity in BC patients
undergoing RT with/without adjuvant chemotherapy.
All of these promising data strongly point to the need
for further investigation in order to set up valuable stra-
tegies to prevent RT-induced damage in cancer patients.
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ray repair cross-complementation group 1; XRCC3: x-ray repair cross-
complementation group 3; WBI: whole breast irradiation; 3D-CRT: 3D
conformal radiation therapy.
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